Practice Point Communications News Today

The CAR T-cell therapy lisocabtagene maraleucel produced rapid and durable responses in heavily pretreated patients with relapsed/refractory mantle cell lymphoma.

Filgotinib drops out of US arthritis race: Gilead ends bid for FDA approval Disclosures: Singh reports consulting fees from Clearview healthcare partners, Clinical Care Options, Crealta/Horizon, Fidia, Focus Forward, Medisys, Medscape, Navigant Consulting, Practice Point Communications, Putnam Associates, Spherix, Trio health, UBM, WebMD, the NIH and the American College of Rheumatology, as well as stock option ownership with Charlotte’s Web Holdings and Vaxart Pharmaceuticals, ...